Etodolaccyclodextrin formulations: Physicochemical characterization and in vivo pharmacological studies

Drug Development and Industrial Pharmacy

Volumn 35, Issue 7, 2009, Pages 877-886

  Cappello, Brunella ^a   Di Maio, Clelia ^a   Iervolino, Maria ^a   Miro, Agnese ^a   Calignano, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cyclodextrin; Analgesic activity; Dissolution; Etodolac; G cyclodextrin; Gastric tolerance; Hydroxypropyl cyclodextrin; Inclusion complexes

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; CYCLODEXTRIN; ETODOLAC; GAMMA CYCLODEXTRIN; KLEPTOSE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG TOLERANCE; FREEZE DRYING; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; RAT; SOLID; X RAY; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; METHODOLOGY; MOUSE; PAIN ASSESSMENT; PHYSICAL CHEMISTRY; WISTAR RAT;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; ETODOLAC; MALE; MICE; PAIN MEASUREMENT; PHYSICOCHEMICAL PHENOMENA; RATS; RATS, WISTAR;

EID: 70350645277     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802680263     Document Type: Article

References (33)

1. Szejtli J. (1988). Cyclodextrin technology. Dordrecht: Kluwer Academic Publishers.
2. Duchêne D. (1991). New trends in cyclodextrins and derivates. Paris: Edition de Santé.
3. Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017-1025
4. Uekama K, Hirayama F, Irie T. (1998). Cyclodextrin drug carrier system. Chem Rev, 98:2045-2076
5. Brewster ME, Loftsson T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv Drug Del Rev, 59:645-666
6. Rajewski RA, Stella VJ. (1996). Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci, 85:1142-1169
7. Carrier RL, Miller LA, Ahmed I. (2007). The utility of cyclodextrins for enhancing oral bioavailability. J Control Release, 127:78-99.
8. Balfour JA, Buckley MMT. (1991). Etodolac-A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs, 42:274-299
9. Reynolds JEF. (1996). Martindale, the extra pharmacopeia, 31st ed. London: Royal Pharmaceutical Society.
10. Jones RA. (2001). Etodolac (Lodine): Profile of an established selective COX-2 inhibitor. Inflammopharmacology, 9:63-70.
11. Glaser KA. (1995). Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (Lodine). Inflammopharmacology, 3:335-345
12. Inoue K, Fujisawa H, Motonaga A, Inoue Y, Kyoi T, Ueda F, et al. (1994). Anti-inflammatory effects of etodolac: Comparison with other non-steroidal anti-inflammatory drugs. Biol Pharm Bull, 17:1577-1583
13. Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, et al. (2008). Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 71:156-160
14. Nardella FA, LeFevre JA. (2002). Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with Etodolac. Blood, 99:2625-2626
15. Remington. (2005). The Science and practice of pharmacy, 21st ed. Philadelphia: University of the Sciences in Philadelphia.
16. Insel PA. (1996) Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. The pharmacological basis of therapeutics. New York: Mc Graw-Hill, 635.
17. Milic-Askrabic J, Rajic DS, Tasic LJ, Djuric S, Kása P, Pintye- Hódi K. (1997). Etodolac and solid dispersion with β-cyclodextrin. Drug Dev Ind Pharm, 23:1123-1129
18. Cappello B, Iervolino M, La Rotonda MI, Miro A. (1999). Influence of different cyclodextrins of physicochemical and pharmacological properties of etodolac. Proceedings of the ninth international symposium on cyclodextrins. Santiago De Compostela (Spain), May 31-June 3, 467-470
19. Junco S, Cabral Marques HM. (2000). Complexation properties of etodolac and cyclodextrins prepared by different methods. Cyclodextrin: From basic research to market. 10th international cyclodextrin symposium. Ann Arbor (USA), May 21-24, 108-1113.
20. Higuchi T, Connors KA. (1965). Phase-solubility techniques. Adv Anal Chem Instrum, 4:117-212.
21. Blanco J, Vila-Jato JL, Otero FAS. (1991). Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Dev Ind Pharm, 17:943-957
22. Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol, 27:48-49
23. Inoue Y. (1993). NMR studies of the structural and the properties of cyclodextrins and their inclusion complexes. Annu Rep NMR Spectrosc, 27:59-101.
24. Mucci A, Schenetti L, Vandelli MA, Ruozi B, Forni F. (1999). Evidence of the existence of 2:1 guest-host complexes between diclofenac and cyclodextrins in D2O solutions A1H and 13C NMR study on diclofenac/β-cyclodextrin and diclofenac/2-hydroxypropyl-β-cyclodextrin systems. J Chem Res Synop, 414:1761-1795
25. Zhao D, Liao K, Ma X, Yan X. (2002). Study of the supramolecular inclusion of β-cyclodextrin with andrographolide. J Incl Phenom, 43:259-264
26. Redenti E, Pasini M, Ventura P, Spisni A, Vikman M, Szejtli J. (1993). The terfenadine/β-cyclodextrin inclusion complex. J Incl Phenom, 15:281-292
27. Liu C, Desai KGH, Liu C. (2005). Enhancement of dissolution rate of valdecoxib using solid dispersions with polyethylene glycol 4000. Drug Dev Ind Pharm, 31:1-10.
28. Barbato F, Cappello B, La Rotonda MI, Miro A, Quaglia F. (2003). Diclofenac/β-cyclodextrin binary system: A study in solution and in the solid state. J Incl Phenom, 46:179-185
29. Mura P, Fauci MT, Parrini PL, Furlanetto S, Pinzauti S. (1999). Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. Int J Pharm, 179:117-128 (Pubitemid 29115066)
30. Nakai Y, Yamamoto K, Terada K, Horibe H. (1984). Interaction of tri-O-methyl-β-cyclodextrin with drugs. J Incl Phenom, 2:523-531
31. Hatanaka H, Komada F, Mishima Y, Okumura K. (1993). Improved bioavailability of para-boronophenylalanine by cyclodextrin complexation. J Pharm Sci, 82:1054-1057
32. Chow DD, Karara AH. (1986). Characterization, dissolution and bioavailability in rats of ibuprofen-β-cyclodextrin complex system. Int J Pharm, 28:95-101.
33. Corrigan OI, Stanley T. (1982). Mechanism of drug dissolution rate enhancement from β-cyclodextrin-drug systems. J Pharm Pharmacol, 34:739-744